{"entity":{"id":"nct03478488","kind":"trial","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","aka":[],"tldr":"A phase 3 trial of Envafolimab, Gemcitabine and Oxaliplatin in biliary tract cancer, run by 3D Medicines (Sichuan) Co., Ltd., active and no longer recruiting.","summary":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC is a phase 3 interventional study registered as NCT03478488 by 3D Medicines (Sichuan) Co., Ltd., with 480 participants enrolled, started 2018-04-16 and due to reach its primary completion in 2024-09-10. Interventions recorded: KN035 plus Gemcitabine & oxaliplatin and Gemcitabine & oxaliplatin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03478488","url":"https://clinicaltrials.gov/study/NCT03478488"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["envafolimab","gemcitabine","oxaliplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03478488","phase":"3","setting":"Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study","sponsor":"3D Medicines (Sichuan) Co., Ltd.","enrolled":480,"outcomes":[]},"route":"/trials/nct03478488/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"drug":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}]}}